These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

662 related items for PubMed ID: 27012778

  • 1. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
    Vaduganathan M, Bhatt DL, Cryer BL, Liu Y, Hsieh WH, Doros G, Cohen M, Lanas A, Schnitzer TJ, Shook TL, Lapuerta P, Goldsmith MA, Laine L, Cannon CP, COGENT Investigators.
    J Am Coll Cardiol; 2016 Apr 12; 67(14):1661-71. PubMed ID: 27012778
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
    Chandrasekhar J, Bansilal S, Baber U, Sartori S, Aquino M, Farhan S, Vogel B, Faggioni M, Giustino G, Ariti C, Colombo A, Chieffo A, Kini A, Saporito R, Michael Gibson C, Witzenbichler B, Cohen D, Moliterno D, Stuckey T, Henry T, Pocock S, Dangas G, Gabriel Steg P, Mehran R.
    Catheter Cardiovasc Interv; 2017 Jun 01; 89(7):E217-E225. PubMed ID: 27650638
    [Abstract] [Full Text] [Related]

  • 6. Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel.
    Morneau KM, Reaves AB, Martin JB, Oliphant CS.
    J Manag Care Pharm; 2014 Feb 01; 20(2):187-93. PubMed ID: 24456320
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study.
    Häuptle R, Weilenmann D, Schneider T, Haile SR, Ammann P, Knellwolf C, Borovicka J.
    Wien Med Wochenschr; 2012 Feb 01; 162(3-4):67-73. PubMed ID: 22476595
    [Abstract] [Full Text] [Related]

  • 9. The effects of proton pump inhibition on patient-reported severity of dyspepsia when receiving dual anti-platelet therapy with clopidogrel and low-dose aspirin: analysis from the Clopidogrel and the Optimization of Gastrointestinal Events Trial.
    Vardi M, Cryer BL, Cohen M, Lanas A, Schnitzer TJ, Lapuerta P, Goldsmith MA, Laine L, Doros G, Liu Y, McIntosh AI, Cannon CP, Bhatt DL.
    Aliment Pharmacol Ther; 2015 Aug 01; 42(3):365-74. PubMed ID: 26032114
    [Abstract] [Full Text] [Related]

  • 10. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial.
    Gargiulo G, Costa F, Ariotti S, Biscaglia S, Campo G, Esposito G, Leonardi S, Vranckx P, Windecker S, Valgimigli M.
    Am Heart J; 2016 Apr 01; 174():95-102. PubMed ID: 26995375
    [Abstract] [Full Text] [Related]

  • 11. [Does dual antiplatelet therapy always require gastroprotection? Tailored medical therapy should prevail over the generalized prescription of proton pump inhibitors in patients on dual antiplatelet therapy].
    Marcucci R.
    G Ital Cardiol (Rome); 2010 Jun 01; 11(6):481-7; discussion 487. PubMed ID: 20922874
    [No Abstract] [Full Text] [Related]

  • 12. Similar Efficacy of Proton-Pump Inhibitors vs H2-Receptor Antagonists in Reducing Risk of Upper Gastrointestinal Bleeding or Ulcers in High-Risk Users of Low-Dose Aspirin.
    Chan FK, Kyaw M, Tanigawa T, Higuchi K, Fujimoto K, Cheong PK, Lee V, Kinoshita Y, Naito Y, Watanabe T, Ching JY, Lam K, Lo A, Chan H, Lui R, Tang RS, Sakata Y, Tse YK, Takeuchi T, Handa O, Nebiki H, Wu JC, Abe T, Mishiro T, Ng SC, Arakawa T.
    Gastroenterology; 2017 Jan 01; 152(1):105-110.e1. PubMed ID: 27641510
    [Abstract] [Full Text] [Related]

  • 13. Combined clopidogrel and proton pump inhibitor therapy is associated with higher cardiovascular event rates after percutaneous coronary intervention: a report from the BASKET trial.
    Burkard T, Kaiser CA, Brunner-La Rocca H, Osswald S, Pfisterer ME, Jeger RV, BASKET Investigators.
    J Intern Med; 2012 Mar 01; 271(3):257-63. PubMed ID: 21726302
    [Abstract] [Full Text] [Related]

  • 14. Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry.
    Aihara H, Sato A, Takeyasu N, Nishina H, Hoshi T, Akiyama D, Kakefuda Y, Watabe H, Aonuma K, ICAS Registry Investigators.
    Catheter Cardiovasc Interv; 2012 Oct 01; 80(4):556-63. PubMed ID: 22234956
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effects of proton pump inhibitors on adverse gastrointestinal events in patients receiving clopidogrel: systematic review and meta-analysis.
    Kwok CS, Nijjar RS, Loke YK.
    Drug Saf; 2011 Jan 01; 34(1):47-57. PubMed ID: 21047145
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
    Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ, Nicolela EL, Perin MA, Devito FS, Labrunie A, Salvadori D, Gusmão M, Staico R, Costa JR, de Castro JP, Abizaid AS, Bhatt DL, OPTIMIZE Trial Investigators.
    JAMA; 2013 Dec 18; 310(23):2510-22. PubMed ID: 24177257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.